

**REMARKS**

Claims 3-9 are all the claims pending in the application, claims 5-8 have been allowed, claims 3, 4 and 9 have been rejected.

After entry of this amendment, claims 5-8 will be pending and claims 3, 4 and 9 will be cancelled.

Claim 5 has been amended to incorporate the recitation of the claim from which it depends (claim 3, as set forth in the Amendment filed January 17, 2002, subsequently entered by the Examiner), thereby converting claim 5 into an independent claim.

The specification has been amended to correct grammatical errors. Applicants note that each of these corrections were requested in amendments filed prior to the submission of the revised specification on January 17, 2002. However, these corrections were inadvertently omitted from the revised specification.

No new matter has been added. Entry of this amendment is earnestly solicited.

**I. Rejection of Claims Under 35 U.S.C. §102**

A. At page 2 of the Office Action, the rejection of claims 3 and 9 under 35 U.S.C. §102(b) as being anticipated by JPA 8-169884 ("the '884 application") is maintained.

In response, Applicants note that included herewith is an amendment to the claims canceling claims 3 and 9.

In view of the cancellation of claims 3 and 9, the present rejection is moot. Accordingly, Applicants respectfully request reconsideration and withdrawal of this rejection.

B. At page 2 of the Office Action, claim 4 is rejected under 35 U.S.C. §102(b) as being anticipated.

In response, Applicants note that included herewith is an amendment to the claims canceling claim 4.

In view of the cancellation of claim 4, the present rejection is moot. Accordingly, Applicants respectfully request reconsideration and withdrawal of this rejection.

## **II. Allowed Claims**

At page 2 of the Office Action, the Examiner states that claims 5-8 are considered to be allowable.

As claim 5 currently depends from a rejected base claim, Applicants have amended claim 5 to incorporate the subject matter of the claim from which it depends (claim 3), thereby converting it into an independent claim.

Applicants assert that in view of the amendment to claim 5, each of claims 5-8 are now in condition for allowance.

## **III. Conclusion**

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

AMENDMENT UNDER 37 C.F.R. §1.111  
U.S. Appln. No. 09/601,505

Q60247

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, consisting of a stylized 'D' followed by a large, flowing 'H'.

---

Drew Hissong  
Registration No. 44,765

SUGHRUE MION, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: October 29, 2002

**APPENDIX**  
**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION:**

**The specification is amended as follows:**

**Paragraph 009 is amended as follows:**

Though metabotropic glutamate receptors appear ~~are appeared~~ to be a significant component in the cascades following excessive glutamate release during and after cerebral ischemia, their roles are not yet clear. Particularly, as the activation of mGluR1 and mGluR5 which is coupled to intracellular IP3 system increases intracellular calcium (Nature, 383, 89-92, 1996), continuous excess stimulation of these receptors may cause neuronal cell death.

**Paragraph 010 is amended as follows:**

Regarding the neuroprotective effect of compounds having mGluR1 antagonism in cerebral ischemia, Cozzi ~~Cozz~~ et al. reported that intraventricular administration of AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid) reduced the loss of the neuronal cells found in the CA1 area of ~~in~~ gerbils ~~which~~ exposed to 5 min of cerebral ischemia (Society of Neuroscience Abstracts, vol. 23, 788.2, 1997). However, Henrich-Noack et al. reported that 4C3HPG ((S)-4-carboxy-3-hydroxyphenylglycine), which is an antagonist of ~~at~~ the Group I mGluRs and an agonist of ~~at~~ Group II mGluRs, is effective, but 4CPG ((S)-4-carboxyphenylglycine), which is a selective Group I mGluR ~~mGluRs~~-antagonist is not effective in the same model (Society of Neuroscience Abstracts, vol. 23, 756.8, 1997).

**Paragraph 011 is amended as follows:**

One of the reasons for ~~these~~this-discrepancy is considered to be due to the insufficient efficacy and selectivity of mGluR1 antagonists used in these experiments. Therefore, it is considered that the neuroprotective effect of compounds having mGluR1 antagonism in cerebral ischemia is not clearly confirmed.

**Paragraph 072 is amended as follows:**

Next, the invention is described further in detail based on examples, though the invention is not limited to these examples.

**IN THE CLAIMS:**

**Claims 3, 4 and 9 are canceled.**

**The claims are amended as follows:**

5. (Amended) A The-pharmaceutical composition for treating acute stage ischemic stroke according to claim 3, which comprises a compound having mGluR1 antagonism in an amount effective for treating acute stage ischemic stroke as an active ingredient and a pharmaceutically effective carrier, and wherein said compound has no agonist or antagonist effect on mGluR2, mGluR3, mGluR4, mGluR6 or mGluR7.